JPMorgan analyst James Gordon raised the firm’s price target on Genmab to DKK 3,600 from DKK 3,450 and keeps an Overweight rating on the shares.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GMAB:
- Genmab submits JNDA for epcoritamab to treat patients with R/R LBCL
- Genmab downgraded to Neutral at Citi with risk/reward ‘more balanced’ for 2023
- Genmab downgraded to Neutral from Buy at Citi
- Genmab to hold a virtual investor update
- Genmab announces results from multiple clinical trials evaluating epcoritamab
